Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset

Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset

Software will aid optimizing pre-clinical data management in accordance with global standards and guidelines.

SEOUL, South Korea–(BUSINESS WIRE)–
Certara, Inc. (Nasdaq: CERT), a global leader in Biosimulation, today announced that a Korea Institute of Toxicology (KIT) have decided to implement Certara’s Pinnacle 21 Enterprise data conformance and submission software and SEND Explorer pre-clinical data visualization software . The combination of Pinnacle 21 Enterprise and SEND Explorer enables synergy for meeting global regulatory guidelines and delivering efficiency. The technology optimizes data analysis from a regulatory perspective and allows scientists to gain scientific insight through interactive toxicity data visualization. It also ensures FDA submission-ready SEND, SDTM, and ADaM datasets.

Pinnacle 21 Enterprise is used to validate compliance with the Clinical Data Interchange Standards Consortium (CDISC) standards, which are required by the U.S. Food & Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and recommended by China’s National Medical Products Administration (NMPA) for evaluating regulatory submissions. Pinnacle 21 Enterprise software has been adopted by the FDA and PMDA as well as 24 of the top 25 biopharmaceutical companies by R&D spend.

SEND Explorer is a validated, web-based application that provides advanced viewing, data summarization and visualization capabilities for nonclinical study data. Using SEND Explorer, scientists generate visualizations of single and multiple toxicology studies to inform decisions and quickly address questions from health authorities.

“We expect that using Pinnacle 21 Enterprise will help KIT increase the quality of SEND Datasets for submission to regulatory agencies. In addition, SEND Explorer will help KIT provide advanced analysis including historical data and cross-analysis studies of toxicity tests, that enable sponsors to quickly address questions from the FDA.” said Junyong Lee, Korea Country Sales Director at Certara.

“With SEND Explorer and Pinnacle 21 Enterprise, scientists can more effectively bridge the translational gap between the nonclinical and clinical phases and ensure that they are regulatory ready” added Leif E. Pedersen, President, Software at Certara.

Learn more about Certara software: https://www.certara.com/software/

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services that transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

Emi Akatsu

[email protected]

KEYWORDS: Asia Pacific South Korea

INDUSTRY KEYWORDS: Science Software Biotechnology Research Pharmaceutical Health Technology Clinical Trials

MEDIA:

Logo
Logo

QuantumScape Announces Pricing of Public Offering of Class A Common Stock

 QuantumScape Announces Pricing of Public Offering of Class A Common Stock

SAN JOSE, Calif.–(BUSINESS WIRE)–
QuantumScape Corporation (NYSE: QS), a leader in developing next-generation solid-state lithium-metal batteries, today announced the pricing of an underwritten public offering of 37,500,000 shares of its Class A common stock (the “Shares”) for gross proceeds of $300 million, before deducting the underwriting discount and commissions and estimated offering expenses.

QuantumScape has granted the underwriters a 30-day option to purchase up to an additional 5,625,000 Shares at the public offering price less the underwriting discount. The public offering is expected to close on August 8, 2023, subject to customary closing conditions.

Evercore ISI and Morgan Stanley acted as joint lead book-running managers for the Offering. Goldman Sachs & Co. LLC and UBS Investment Bank acted as additional book-running managers.

The public offering is being made pursuant to a shelf registration statement on Form S-3 that was filed by QuantumScape with the U.S. Securities and Exchange Commission (the “SEC”) on July 29, 2022, and became effective on August 10, 2022. The offering was made only by means of a preliminary prospectus supplement and an accompanying prospectus relating to the offering which have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement will be filed with the SEC, a copy of which may also be obtained by contacting: Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 888-474-0200, or by email at [email protected]; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About QuantumScape Corporation

QuantumScape is on a mission to transform energy storage with solid-state lithium-metal battery technology. The company’s next-generation batteries are designed to enable greater energy density, faster charging and enhanced safety to support the transition away from legacy energy sources toward a lower carbon future.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this release include, but are not limited to, statements concerning the terms, size and completion of the proposed public offering and the anticipated use of proceeds.

These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. The company cautions you that these forward-looking statements are subject to significant risks and uncertainties and other factors that could cause QuantumScape’s development and commercialization timeline and QuantumScape’s actual results to differ materially from current expectations. Information about factors that could materially affect QuantumScape is set forth under the “Risk Factors” section in the QuantumScape’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 28, 2023, and other filings with the SEC available on the SEC’s website at www.sec.gov.

Except as otherwise required by applicable law, QuantumScape disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Should underlying assumptions prove incorrect, actual results and projections could different materially from those expressed in any forward-looking statements.

For Investors

[email protected]

For Media

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology General Automotive EV/Electric Vehicles Other Energy Other Transport Automotive Batteries Alternative Energy Energy Vehicle Technology Transport Other Technology Other Automotive Hardware

MEDIA:

Logo
Logo

Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the US Food and Drug Administration (FDA) has provided a complete response to its Biologics License Application (BLA) resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD) and requires more data to support marketing approval. To obtain the data required, Mesoblast will conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. This adult study is in line with our overall commercial strategy, which envisioned a sequenced progression from pediatric to adult SR-aGVHD indications. Adults comprise 80% of the SR-aGVHD market.

Mesoblast Chief Executive Silviu Itescu said: “FDA’s inspection of our manufacturing process resulted in no observed concerns, the Agency raised no safety issues across more than 1300 patients who have received remestemcel-L to date, and acknowledged improvements to our potency assay. We remain steadfast in making remestemcel-L available to both children and adults suffering from this devastating disease, and have received substantial clarity in how to bring this much-needed product to these patients”.

Mesoblast intends to enroll adult patients at highest mortality risk with SR-aGVHD where existing therapy has not improved outcomes and 90-day survival remains as low as 20-30%.1 Mesoblast has generated pilot data through its emergency IND program in adults showing a survival benefit with remestemcel-L in this target population. In line with our overall commercial strategy to expand into the adult SR-aGVHD indication, Mesoblast has already been working with leading investigators at various US centers of excellence to establish the adult follow-on study protocol, potentially utilizing established clinical trials networks. The company will seek alignment with FDA on the trial design for the adult study at a Type A meeting within 45 days.

Prior to the resubmission, FDA guided Mesoblast to resolve outstanding chemistry, manufacturing and controls (CMC) issues before initiating any additional clinical trial. FDA completed the Pre-License Inspection (PLI) of the manufacturing facility, did not issue any Form 483, and found no objectionable conditions. In addition, FDA acknowledged in the resubmission review that changes implemented appear to improve assay performance relative to the original version of the assay used in the pediatric Phase 3 trial.

Mesoblast has successfully met the pre-specified primary endpoint, prospectively agreed with FDA, of a single-arm Phase 3 trial in 54 children with SR-aGvHD. While the Oncologic Drugs Advisory Committee of FDA in August 2020 voted 9:1 in favor of remestemcel-L’s efficacy in a pediatric patient population, in September 2020 FDA recommended further steps be undertaken to obtain approval. The BLA resubmission of January 2023 included long-term follow-up data from the Phase 3 trial by the Center for International Blood and Marrow Transplant Research (CIBMTR) showing 50% survival through more than 4 years of follow-up for remestemcel-L treated patients in the Phase 3 trial for whom less than 20% survival at two years was expected based on disease severity. The resubmission also included a post-hoc propensity matched study showing 6 month survival was 67% with remestemcel-L vs 10% with other unapproved therapies in highest-risk patients as identified using the Mount Sinai Acute GVHD International Consortium (MAGIC). These pediatric data provide further support for use of remestemcel-L in the proposed study in high-risk adults with SR-aGVHD.

Conference Call

There will be a webcast today, beginning at 8.00pm EDT (Thursday, August 3); 10.00am AEST (Friday, August 4);. It can be accessed via: https://webcast.openbriefing.com/msb-mu-2023/

The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com

About Steroid-Refractory Acute Graft Versus Host Disease

Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, including about 20% in pediatric patients.2,3

First-line treatment involves systemic corticosteroids. A significant proportion of patients have severe disease that is refractory to steroids. SR-aGVHD is associated with mortality as high as 90% and significant extended hospital stay costs.4,5

About Mesoblast

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

References / Footnotes

  1. Jagasia M et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749
  2. Niederwieser D, Baldomero H, Szer J. (2016) Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey.
  3. HRSA Transplant Activity Report, CIBMTR, 2019
  4. Westin, J., Saliba, RM., Lima, M. (2011) Steroid-refractory acute GVHD: predictors and outcomes. Advances in Hematology.
  5. Axt L, Naumann A, Toennies J (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation.

Forward-Looking Statements

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals (including our request to have a Type A meeting with the FDA, the outcome of such a meeting, and any future decision that the FDA may make on the BLA for remestemcel-L for pediatric patients with SR-aGVHD), manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:


Corporate Communications / Investors

Media
Paul Hughes BlueDot Media
T: +61 3 9639 6036 Steve Dabkowski
E: [email protected] T: +61 419 880 486
  E: [email protected]
   
  Rubenstein
  Tali Mackay
  E: [email protected]
   
   



HEI Declares Quarterly Dividend of $0.36 Per Share

HEI Declares Quarterly Dividend of $0.36 Per Share

HONOLULU–(BUSINESS WIRE)–
On August 3, 2023, the Board of Directors of Hawaiian Electric Industries, Inc. (HEI) (NYSE: HE) declared a quarterly cash dividend of $0.36 per share, payable September 8, 2023, to shareholders of record at the close of business on August 18, 2023 (ex-dividend date of August 17, 2023). The dividend is equivalent to an annual rate of $1.44 per share.

Dividends have been paid on an uninterrupted basis since 1901. At the indicated annual dividend rate and based on the closing share price on August 3, 2023 of $37.72, HEI’s dividend yield is 3.8%.

HEI and Hawaiian Electric Company, Inc. (Hawaiian Electric) intend to continue to use HEI’s website, www.hei.com, as a means of disclosing additional information; such disclosures will be included in the Investor Relations section of the website. Accordingly, investors should routinely monitor the Investor Relations section of HEI’s website, in addition to following HEI’s, Hawaiian Electric’s and American Savings Bank’s press releases, HEI’s and Hawaiian Electric’s Securities and Exchange Commission (SEC) filings and HEI’s public conference calls and webcasts. Investors may sign up to receive e-mail alerts via the Investor Relations section of the website. The information on HEI’s website is not incorporated by reference into this document or into HEI’s and Hawaiian Electric’s SEC filings unless, and except to the extent, specifically incorporated by reference.

Investors may also wish to refer to the Public Utilities Commission of the State of Hawaii (PUC) website at dms.puc.hawaii.gov/dms to review documents filed with, and issued by, the PUC. No information on the PUC website is incorporated by reference into this document or into HEI’s and Hawaiian Electric’s SEC filings.

About HEI

The HEI family of companies provides the energy and financial services that empower much of the economic and community activity of Hawaii. HEI’s electric utility, Hawaiian Electric, supplies power to approximately 95% of Hawaii’s population and is undertaking an ambitious effort to decarbonize its operations and the broader state economy. Its banking subsidiary, American Savings Bank, is one of Hawaii’s largest financial institutions, providing a wide array of banking and other financial services and working to advance economic growth, affordability and financial fitness. HEI also helps advance Hawaii’s sustainability goals through investments by its non-regulated subsidiary, Pacific Current. For more information, visit www.hei.com.

Mateo Garcia

Director, Investor Relations

Telephone: (808) 543-7300

E-mail: [email protected]

KEYWORDS: Hawaii United States North America

INDUSTRY KEYWORDS: Utilities Sustainability Environment Finance Energy Banking Professional Services Green Technology

MEDIA:

Logo
Logo

UPDATE – NN, Inc. Reports Financial Results for Second Quarter 2023

Business transformation fully underway as enhanced strategic initiatives building momentum

CHARLOTTE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that manufactures high-precision components and assemblies, today reported its financial results for the second quarter ended June 30, 2023.

Financial and Strategic Highlights

  • Net sales of $125.2 million flat versus prior year period;
  • Operating loss of $4.0 million and Adjusted EBITDA of $10.5 million;
  • Free cash flow results of $3.0 million with positive free cash flow generation over the trailing year;
  • Key program wins including attractive wins in EV electric power steering markets;
  • Revised second half forecast based on softening market conditions;
  • New leadership executing strategic transformation;
  • Announced streamlining of Board of Directors;
  • Integration of sales and operations teams to accelerate growth and utilize existing capacity;
  • Addressing three underperforming facilities and several unprofitable customer agreements; and
  • Prioritizing free cash flow generation through operations and cost management.

Harold Bevis, President and Chief Executive Officer, commented, “Our team has embraced the need for meaningful change and is taking aggressive action to transform the company. Multiple transformation initiatives are underway and are being led by an experienced NN team which has been supplemented by additional talent. The goal is to improve performance faster in both the short-term and long-term. Over the second half of 2023 we are focused on the following: 1) delivering higher rates of new business wins by leveraging existing open capacity and targeted new capacity; 2) containing and eliminating operating losses at a few select plants and within certain customer agreements; 3) installing an evergreen cost productivity and margin expansion regimen; and, lastly 4) investing into the business and delivering net free cash flow.”

Bevis continued, “NN has unique precision machining and stamping capabilities and a huge global installed base of machinery. We are experts at what we do and a member of a select set of companies that can deliver precision components at a sub-micron level. We have historically been focused on a few long-cycle markets but are expanding our commercial aperture to include multiple other markets that our machines and people can serve including medical, electrification, and next-generation vehicles. Our focus is clear, and we have the right team, platform and capabilities to significantly accelerate our growth and profitability.”

Michael Felcher, Senior Vice President and Chief Financial Officer, commented, “While our sales were flat compared to last year’s second quarter, the impact of softer, macro-driven volumes was offset by pricing secured by our commercial teams. The impact of facility closures and other cost reductions was evident in our results as our operating income performance improved versus both the prior year period and this year’s first quarter. We delivered $10.5 million of Adjusted EBITDA in the quarter, helping drive solid cash flows from operations. Our strategic transformation efforts are helping position the Company for stronger structural profitability and improved cash returns, as demonstrated through converting our improved operating cash flows into $3.0 million of free cash flow. Encouragingly, we have now generated positive free cash flow over the trailing year and remain focused on incrementally improving these results as we move forward.”


Second Quarter GAAP Results

Net sales were $125.2 million, a decrease of 0.1% from the second quarter of 2022, primarily due to reduced volume and unfavorable foreign exchange effects, partially offset by higher customer pricing.

Loss from operations was $4.0 million compared to a loss from operations of $4.5 million in the second quarter of 2022. The decrease in loss from operations was primarily driven by labor cost reductions and facility closures, offset by lower volumes.

Income from operations for Power Solutions was $2.6 million compared to income from operations of $1.4 million for the same period in 2022. Loss from operations for Mobile Solutions was $1.5 million compared to income from operations of $1.7 million for the same period in 2022.

Net loss was $14.4 million compared to net loss of $8.6 million for the same period in 2022. The increase in net loss is due to reduced sales volume and unfavorable warrant revaluations, partially offset by pricing in excess of inflation.


Second Quarter Adjusted Results

Adjusted income from operations for the second quarter of 2023 was $1.3 million compared to adjusted income from operations of $0.1 million for the same period in 2022. Adjusted EBITDA was $10.5 million, or 8.4% of sales, compared to $10.9 million, or 8.7% of sales, for the same period in 2022. Adjusted net loss was $3.3 million, or $0.08 per diluted share, compared to adjusted net loss of $3.6 million, or $0.09 per diluted share, for the same period in 2022.

Free cash flow was a generation of cash of $3.0 million compared to a use of cash of $2.4 million for the same period in 2022.


Power Solutions

Net sales for the second quarter of 2023 were $48.1 million compared to $52.0 million in the second quarter of 2022, a decrease of 7.7% or $4.0 million. The decrease in sales was primarily due to lower volume, partially offset by higher pricing and favorable foreign exchange effects. Adjusted income from operations was $5.6 million compared to adjusted income from operations of $4.6 million in the second quarter of 2022. The increase in adjusted income from operations was primarily due to facility closure savings, partially offset by lower volumes.


Mobile Solutions

Net sales for the second quarter of 2023 were $77.2 million compared to $73.4 million in the second quarter of 2022, an increase of 5.2% or $3.8 million. The increase in sales was primarily due to higher customer pricing, partially offset by lower volume and unfavorable foreign exchange effects. Adjusted income from operations was $0.2 million compared to adjusted income from operations of $2.6 million in the second quarter of 2022. The decrease in adjusted income from operations was primarily driven by volume reductions and a favorable customer settlement in the prior year.


2023 Outlook

Based on results for the first half of the year, as well as expectations for the remainder of the year, the Company has revised its expectations for financial results for the full year as follows:

  • Revenue in the range of $485 million to $505 million;
  • Adjusted EBITDA in the range of $40 million to $46 million; and
  • Free cash flow in the range of $7 to $13 million.

Free cash flow outlook does not include the CARES Act tax refund of ~$11 million due to uncertain timing.

Michael Felcher, Senior Vice President and Chief Financial Officer commented, “While our second quarter results showed encouraging signs of improvement, we are revising our previous full-year 2023 financial outlook in line with year-to-date performance and our expectations and assumptions for the back half of the year. Our sales and Adjusted EBITDA outlook reflects our expectation that overall demand levels will remain consistent with the first half of the year, compared to the prior expectation of increasing demand. Our free cash flow outlook reflects the impact of lower volume and disciplined cash management.”


Conference Call

NN will discuss its results during its quarterly investor conference call on August 4, 2023, at 9:00 a.m. ET. The call and supplemental presentation may be accessed via NN’s website, www.nninc.com. The conference call can also be accessed by dialing 1-877-317-6789 or 1-412-317-6789. For those who are unavailable to listen to the live broadcast, a replay will be available shortly after the call until August 4, 2024.

NN discloses in this press release the non-GAAP financial measures of adjusted income (loss) from operations, adjusted EBITDA, adjusted net income (loss), adjusted net income (loss) per diluted common share, and free cash flow. Each of these non-GAAP financial measures provides supplementary information about the impacts of restructuring and integration expense, acquisition and transition expenses, foreign exchange impacts on inter-company loans, amortization of intangibles and deferred financing costs, and other non-operating impacts on our business.

The financial tables found later in this press release include a reconciliation of adjusted income (loss) from operations, adjusted operating margin, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per diluted share, free cash flow to the U.S. GAAP financial measures of income (loss) from operations, net income (loss), net income (loss) per diluted common share, and cash provided (used) by operating activities.


About NN, Inc

.

NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

Except for specific historical information, many of the matters discussed in this press release may express or imply projections of revenues or expenditures, statements of plans and objectives or future operations or statements of future economic performance. These statements may discuss goals, intentions and expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to NN, Inc. based on current beliefs of management as well as assumptions made by, and information currently available to, management. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,”, “will” “possible,” “potential,” “predict,” “project” or other similar words, phrases or expressions. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such forward-looking statements. Such factors include, among others, general economic conditions and economic conditions in the industrial sector; the impacts of pandemics, epidemics, disease outbreaks and other public health crises, including the COVID-19 pandemic, on our financial condition, business operations and liquidity; competitive influences; risks that current customers will commence or increase captive production; risks of capacity underutilization; quality issues; material changes in the costs and availability of raw materials; economic, social, political and geopolitical instability, currency fluctuation, and other risks of doing business outside of the United States; inflationary pressures and changes in the cost or availability of materials, supply chain shortages and disruptions, and the availability of labor; our dependence on certain major customers, some of whom are not parties to long-term agreements (and/or are terminable on short notice); the impact of acquisitions and divestitures; our ability to hire or retain key personnel; the level of our indebtedness; the restrictions contained in our debt agreements; our ability to obtain financing at favorable rates, if at all, and to refinance existing debt as it matures; unanticipated difficulties integrating acquisitions; new laws and governmental regulations; the impact of climate change on our operations; and cyber liability or potential liability for breaches of our or our service providers’ information technology systems or business operations disruptions. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor & Media Contacts:

Joe Caminiti or Alec Steinberg, Investors
Tim Peters, Media
[email protected]
312-445-2870

Financial Tables Follow



NN, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)
       
  Three Months Ended

June 30,
  Six Months Ended

June 30,

(in thousands, except per share data)
  2023       2022       2023       2022  
Net sales $ 125,206     $ 125,362     $ 252,294     $ 253,429  
Cost of sales (exclusive of depreciation and amortization shown separately below)   107,684       103,889       216,105       208,467  
Selling, general, and administrative expense   10,975       14,794       24,140       28,248  
Depreciation and amortization   11,550       11,340       23,066       22,769  
Other operating expense (income), net   (956 )     (147 )     105       1,879  
Loss from operations   (4,047 )     (4,514 )     (11,122 )     (7,934 )
Interest expense   5,457       3,488       9,745       6,927  
Other expense (income), net   5,641       (67 )     3,433       (3,063 )
Loss before provision for income taxes and share of net income from joint venture   (15,145 )     (7,935 )     (24,300 )     (11,798 )
Provision for income taxes   (325 )     (1,051 )     (1,626 )     (2,582 )
Share of net income from joint venture   1,093       419       1,374       2,511  
Net loss $ (14,377 )   $ (8,567 )   $ (24,552 )   $ (11,869 )
Other comprehensive loss:              
Foreign currency transaction loss   (2,374 )     (8,490 )     (534 )     (5,890 )
Interest rate swap:              
Change in fair value, net of tax         373       (230 )     1,560  
Reclassification adjustment for losses (gains) included in net loss, net of tax   (449 )     31       (917 )     65  
Other comprehensive loss $ (2,823 )   $ (8,086 )   $ (1,681 )   $ (4,265 )
Comprehensive loss $ (17,200 )   $ (16,653 )   $ (26,233 )   $ (16,134 )
Basic net loss per common share:              
Net loss per common share $ (0.38 )   $ (0.25 )   $ (0.67 )   $ (0.38 )
Weighted average common shares outstanding   46,357       44,708       45,836       44,649  
Diluted net loss per common share:              
Net loss per common share $ (0.38 )   $ (0.25 )   $ (0.67 )   $ (0.38 )
Weighted average common shares outstanding   46,357       44,708       45,836       44,649  

 
 
NN, Inc.

Condensed Consolidated Balance Sheets

(Unaudited) 
       

(in thousands, except per share data)
June 30,

2023
  December 31,

2022
Assets      
Current assets:      
Cash and cash equivalents $ 14,337     $ 12,808  
Accounts receivable, net   79,302       74,129  
Inventories   77,386       80,682  
Income tax receivable   12,496       12,164  
Prepaid assets   4,653       2,794  
Other current assets   9,243       9,123  
Total current assets   197,417       191,700  
Property, plant and equipment, net   192,241       197,637  
Operating lease right-of-use assets   44,924       46,713  
Intangible assets, net   65,765       72,891  
Investment in joint venture   31,570       31,802  
Deferred tax assets   102       102  
Other non-current assets   6,395       5,282  
Total assets $ 538,414     $ 546,127  
Liabilities, Preferred Stock, and Stockholders’ Equity      
Current liabilities:      
Accounts payable $ 51,416     $ 45,871  
Accrued salaries, wages and benefits   13,317       11,671  
Income tax payable   485       926  
Current maturities of long-term debt   6,810       3,321  
Current portion of operating lease liabilities   5,361       5,294  
Other current liabilities   13,630       11,723  
Total current liabilities   91,019       78,806  
Deferred tax liabilities   5,728       5,596  
Long-term debt, net of current portion   148,636       149,389  
Operating lease liabilities, net of current portion   49,149       51,411  
Other non-current liabilities   18,490       9,960  
Total liabilities   313,022       295,162  
Commitments and contingencies      
Series D perpetual preferred stock – $0.01 par value per share, 65 shares authorized, issued and outstanding at June 30, 2023 and December 31, 2022   70,948       64,701  
Stockholders’ equity:      
Common stock – $0.01 par value per share, 90,000 shares authorized, 47,019 and 43,856 shares issued and outstanding at June 30, 2023 and December 31, 2022   470       439  
Additional paid-in capital   462,525       468,143  
Accumulated deficit   (269,750 )     (245,198 )
Accumulated other comprehensive loss   (38,801 )     (37,120 )
Total stockholders’ equity   154,444       186,264  
Total liabilities, preferred stock, and stockholders’ equity $ 538,414     $ 546,127  

 
 
NN, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)
   
  Six Months Ended

June 30,

(in thousands) 
  2023       2022  
Cash flows from operating activities      
Net loss $ (24,552 )   $ (11,869 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization   23,066       22,769  
Amortization of debt issuance costs and discount   880       662  
Paid-in-kind interest   744        
Total derivative loss (gain), net of cash settlements   5,691       (3,237 )
Share of net income from joint venture   (1,374 )     1,515  
Compensation expense from issuance of share-based awards   851       3,555  
Deferred income taxes   110       94  
Other   (721 )     (2,763 )
Changes in operating assets and liabilities:      
Accounts receivable   (5,078 )     (13,264 )
Inventories   3,920       (10,586 )
Accounts payable   6,927       11,960  
Income taxes receivable and payable, net   (730 )     (475 )
Other   (1,091 )     (905 )
Net cash provided by (used in) operating activities   8,643       (2,544 )
Cash flows from investing activities      
Acquisition of property, plant and equipment   (12,196 )     (9,703 )
Proceeds from sale of property, plant, and equipment   2,777       422  
Net cash used in investing activities   (9,419 )     (9,281 )
Cash flows from financing activities      
Proceeds from long-term debt   35,000       20,000  
Repayments of long-term debt   (34,725 )     (19,482 )
Cash paid for debt issuance costs   (55 )      
Repayments of short-term debt, net   3,648        
Other   (1,610 )     (1,528 )
Net cash provided by (used in) financing activities   2,258       (1,010 )
Effect of exchange rate changes on cash flows   47       (635 )
Net change in cash and cash equivalents   1,529       (13,470 )
Cash and cash equivalents at beginning of period   12,808       28,656  
Cash and cash equivalents at end of period $ 14,337     $ 15,186  

 
 
Reconciliation of GAAP Income (Loss) from Operations to Non-GAAP Adjusted Income (Loss) from Operations
               

(in thousands)
  Three Months Ended
June 30,

 
NN, Inc. Consolidated   2023       2022  
GAAP income (loss) from operations $ (4,047 )   $ (4,514 )
Professional fees   119       678  
Personnel costs (1)   622       17  
Facility costs (2)   1,022       333  
Amortization of intangibles   3,563       3,586  
Fixed asset impairments         (14 )
Non-GAAP adjusted income (loss) from operations (a) $ 1,279     $ 86  
       
Non-GAAP adjusted operating margin (3)   1.0 %     0.1 %
GAAP net sales $ 125,206     $ 125,362  
       
       

(in thousands)
  Three Months Ended
June 30,





 
Power Solutions   2023       2022  
GAAP income (loss) from operations $ 2,583     $ 1,430  
Professional fees         165  
Facility costs (2)   244       274  
Amortization of intangibles   2,724       2,747  
Non-GAAP adjusted income (loss) from operations (a) $ 5,551     $ 4,616  
       
Non-GAAP adjusted operating margin (3)   11.5 %     8.9 %
GAAP net sales $ 48,062     $ 52,049  

               
               

(in thousands)
  Three Months Ended
June 30,





 
Mobile Solutions   2023       2022  
GAAP income (loss) from operations $ (1,461 )   $ 1,729  
Personnel costs (1)   40        
Facility costs (2)   778       59  
Amortization of intangibles   838       839  
Fixed asset impairments         (14 )
Non-GAAP adjusted income (loss) from operations (a)   195       2,613  
       
Share of net income from joint venture   1,093       419  
Non-GAAP adjusted income (loss) from operations with JV $ 1,288     $ 3,032  
       
Non-GAAP adjusted operating margin (3)   1.7 %     4.1 %
GAAP net sales $ 77,153     $ 73,350  
       
       

(in thousands)
  Three Months Ended
June 30,





 
Elimination   2023       2022  
GAAP net sales $ (9 )   $ (37 )
       
       
(1) Personnel costs include recruitment, retention, relocation, and severance costs
(2) Facility costs include costs associated with opening or closing facilities and equipment relocation
(3) Non-GAAP adjusted operating margin = Non-GAAP adjusted income (loss) from operations / GAAP net sales

 
 
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA
               
    Three Months Ended June 30,  

(in thousands)
  2023       2022  
GAAP net income (loss) $ (14,377 )   $ (8,567 )
       
Provision for income taxes   325       1,051  
Interest expense   5,457       3,488  
Change in fair value of preferred stock derivatives and warrants   5,754       (694 )
Depreciation and amortization   11,550       11,340  
Professional fees   119       678  
Personnel costs (1)   622       17  
Facility costs (2)   1,022       333  
Non-cash stock compensation   471       2,607  
Non-cash foreign exchange (gain) loss on inter-company loans   (445 )     654  
Fixed asset impairments         (14 )
Non-GAAP adjusted EBITDA (b) $ 10,498     $ 10,893  
       
Non-GAAP adjusted EBITDA margin (4)   8.4 %     8.7 %
GAAP net sales $ 125,206     $ 125,362  
               
(4) Non-GAAP adjusted EBITDA margin = Non-GAAP adjusted EBITDA / GAAP net sales

 
 
Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted Net Income and GAAP Net Income (Loss)

per Diluted Common Share to Non-GAAP Adjusted Net Income (Loss) per Diluted Common Share
   
  Three Months Ended June 30,

(in thousands)
  2023       2022  
GAAP net income (loss) $ (14,377 )   $ (8,567 )
       
Pre-tax professional fees   119       678  
Pre-tax personnel costs   622       17  
Pre-tax facility costs   1,022       333  
Pre-tax foreign exchange (gain) loss on inter-company loans   (445 )     654  
Pre-tax change in fair value of preferred stock derivatives and warrants   5,754       (694 )
Pre-tax amortization of intangibles and deferred financing costs   4,090       3,916  
Pre-tax impairments of fixed asset costs         (14 )
Tax effect of adjustments reflected above (c)   (64 )     (1,027 )
Non-GAAP discrete tax adjustments         1,098  
Non-GAAP adjusted net income (loss) (d) $ (3,279 )   $ (3,606 )
       
   
  Three Months Ended June 30,

(per diluted common share)
  2023       2022  
GAAP net income (loss) per diluted common share $ (0.38 )   $ (0.25 )
       
Pre-tax professional fees         0.01  
Pre-tax personnel costs   0.01        
Pre-tax facility costs   0.02       0.01  
Pre-tax foreign exchange (gain) loss on inter-company loans   (0.01 )     0.01  
Pre-tax change in fair value of preferred stock derivatives and warrants   0.12       (0.02 )
Pre-tax amortization of intangibles and deferred financing costs   0.09       0.09  
Tax effect of adjustments reflected above (c)         (0.02 )
Non-GAAP discrete tax adjustments         0.02  
Preferred stock cumulative dividends and deemed dividends   0.07       0.06  
Non-GAAP adjusted net income (loss) per diluted common share (d) $ (0.08 )   $ (0.09 )
Weighted average common shares outstanding   46,357       44,708  

 
 
Reconciliation of Operating Cash Flow to Free Cash Flow
   
  Three Months Ended

June 30,

(in thousands)
  2023       2022  
Net cash provided (used) by operating activities $ 8,417     $ 2,661  
Acquisition of property, plant, and equipment   (7,199 )     (5,441 )
Proceeds from sale of property, plant, and equipment   1,742       386  
Free cash flow $ 2,960     $ (2,394 )

                                     

The Company discloses in this presentation the non-GAAP financial measures of adjusted income (loss) from operations, adjusted EBITDA, adjusted net income (loss), adjusted net income (loss) per diluted common share, and free cash flow. Each of these non-GAAP financial measures provides supplementary information about the impacts of acquisition, divestiture and integration related expenses, foreign-exchange impacts on inter-company loans, reorganizational and impairment charges. Over the past five years, we have completed several acquisitions, one of which was transformative for the Company, and sold two of our businesses. The costs we incurred in completing such acquisitions, including the amortization of intangibles and deferred financing costs, and these divestitures have been excluded from these measures because their size and inconsistent frequency are unrelated to our commercial performance during the period, and which we believe are not indicative of our ongoing operating costs. We exclude the impact of currency translation from these measures because foreign exchange rates are not under management’s control and are subject to volatility. Other non-operating charges are excluded as the charges are not indicative of our ongoing operating cost. We believe the presentation of adjusted income (loss) from operations, adjusted EBITDA, adjusted net income (loss), adjusted net income (loss) per diluted common share, and free cash flow provides useful information in assessing our underlying business trends and facilitates comparison of our long-term performance over given periods.

The non-GAAP financial measures provided herein may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies may calculate such financial results differently. The Company’s non-GAAP financial measures are not measurements of financial performance under GAAP and should not be considered as alternatives to actual income growth derived from income amounts presented in accordance with GAAP. The Company does not consider these non-GAAP financial measures to be a substitute for, or superior to, the information provided by GAAP financial results.

(a) Non-GAAP Adjusted income (loss) from operations represents GAAP income (loss) from operations, adjusted to exclude the effects of restructuring and integration expense; non-operational charges related to acquisition and transition expense, intangible amortization costs for fair value step-up in values related to acquisitions, non-cash impairment charges, and when applicable, our share of income from joint venture operations. We believe this presentation is commonly used by investors and professional research analysts in the valuation, comparison, rating, and investment recommendations of companies in the industrial industry. We use this information for comparative purposes within the industry. Non-GAAP adjusted income (loss) from operations is not a measure of financial performance under GAAP and should not be considered as a measure of liquidity or as an alternative to GAAP income (loss) from operations.

(b) Non-GAAP adjusted EBITDA represents GAAP net income (loss), adjusted to include income taxes, interest expense, write-off of unamortized debt issuance costs, interest rate swap payments and change in fair value that was recognized in earnings, change in fair value of preferred stock derivatives and warrants, depreciation and amortization, charges related to acquisition and transition costs, non-cash stock compensation expense, foreign exchange gain (loss) on inter-company loans, restructuring and integration expense, costs related to divested businesses and litigation settlements, income from discontinued operations, and non-cash impairment charges, to the extent applicable. We believe this presentation is commonly used by investors and professional research analysts in the valuation, comparison, rating, and investment recommendations of companies in the industrial industry. We use this information for comparative purposes within the industry. Non-GAAP adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as a measure of liquidity or as an alternative to GAAP income (loss) from continuing operations.

(c) This line item reflects the aggregate tax effect of all non-tax adjustments reflected in the respective table. NN, Inc. estimates the tax effect of the adjustment items identified in the reconciliation schedule above by applying the applicable statutory rates by tax jurisdiction unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment.

(d) Non-GAAP adjusted net income (loss) represents GAAP net income (loss) adjusted to exclude the tax-affected effects of charges related to acquisition and transition costs, foreign exchange gain (loss) on inter-company loans, restructuring and integration charges, amortization of intangibles costs for fair value step-up in values related to acquisitions and amortization of deferred financing costs, non-cash impairment charges, write-off of unamortized debt issuance costs, interest rate swap payments and change in fair value, change in fair value of preferred stock derivatives and warrants, costs related to divested businesses and litigation settlements, income (loss) from discontinued operations, and preferred stock cumulative dividends and deemed dividends. We believe this presentation is commonly used by investors and professional research analysts in the valuation, comparison, rating, and investment recommendations of companies in the industrial industry. We use this information for comparative purposes within the industry.

 



Pixie Dust Technologies, Inc. Announces Closing of Initial Public Offering

Pixie Dust Technologies, Inc. Announces Closing of Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Pixie Dust Technologies, Inc. (NasdaqCM: PXDT) (the “Company”), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology, today announced that it has closed the previously announced initial public offering (the “Offering”) of 1,666,667 American Depositary Shares (the “ADSs”, and each, an “ADS”), each ADS representing one common share of the Company, at a price of $9.00 per ADS for gross proceeds of approximately $15.0 million, before underwriting discounts and commissions. Net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses, were approximately $11.2 million. The Company intends to use the net proceeds for the development and commercialization of its technologies and related products, and for other working capital and general corporate purposes.

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 250,000 ADSs, representing an additional 250,000 common shares of the Company, at the Offering price, less underwriting discounts and commissions.

Boustead Securities, LLC acted as the lead book-running manager for the Offering.

The ADSs were offered pursuant to the Company’s Registration Statement on Form F-1 (File No. 333-272476) previously filed with, and subsequently declared effective by, the U.S. Securities and Exchange Commission (the “SEC”) on July 31, 2023. This Offering was made only by means of a prospectus forming part of the Registration Statement relating to these ADSs. A final prospectus relating to the Offering was filed with the SEC on August 2, 2023 and is available for free on the SEC’s website at http://www.sec.gov. Electronic copies of the prospectus relating to the Offering may be obtained from Boustead Securities, LLC, 6 Venture, Suite 395, Irvine, California 92618, by phone at +1-949-502-4408 or by email at [email protected].

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction, including Japan.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the Company’s current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including the strength of the economy, changes to the market for securities, political or financial instability and other factors which are set forth in the Company’s Registration Statement on Form F-1 (File No. 333-272476), as amended, and in all filings with the SEC made by the Company subsequent to the filing thereof. The Company does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

About Pixie Dust Technologies, Inc.

Pixie Dust Technologies, Inc. is a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave technology. The Company is currently focusing on two areas of product development: (1) “Personal Care & Diversity”, where wave control technology is applied to mechanobiology and intervention/assistance in vision, hearing, and touch, and (2) “Workspace & Digital Transformation,” where metamaterials (technology that creates properties through structure rather than material) and solutions to commercial design problems, such as in offices or construction sites, are applied.

Pixie Dust Technologies Investor Relations Contact:

Email: [email protected]

Gateway Group, Inc.

John Yi and Luke Johnson

Email: [email protected]

Underwriter Inquiries:

Boustead Securities, LLC

(949) 502-4408

[email protected]

KEYWORDS: United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Consumer Electronics Technology Other Technology Manufacturing Other Manufacturing Hardware

MEDIA:

Avista reaches all-party, all-issues settlement in Oregon general rate case

If approved, new rates would take effect beginning January 1, 2024

SPOKANE, Wash., Aug. 03, 2023 (GLOBE NEWSWIRE) — Avista (NYSE: AVA), the Staff of the Public Utility Commission of Oregon (Commission), the Oregon Citizens’ Utility Board (“CUB”), Alliance of Western Energy Consumers (“AWEC”), and the joint intervenor Sierra Club/Climate Solutions, parties to the Company’s natural gas general rate case, have reached a settlement agreement that has been submitted to the Commission for its consideration, and which would resolve all remaining issues in the proceeding.

If approved, this settlement would result in a base revenue increase request of $7.16 million (or 4.7%), as compared to Avista’s original request of $11.0 million. The agreed-upon revenue requirement is predicated on a proposed rate of return of 7.235% with a common equity ratio of 50% and a 9.5% return on equity.

“This settlement agreement will provide new rates in Oregon that are fair and reasonable for our customers, the Company, and our shareholders,” said Dennis Vermillion, Avista president and CEO. “This outcome allows us to recover our costs in a timely manner and supports Avista’s efforts to invest in and maintain our infrastructure so we can continue to provide the reliable energy our customers expect.”

Residential Customer Bills

If the settlement is approved, a residential natural gas customer using an average of 47 therms per month, would see a $4.07 per month increase, or 5.3 percent, from a $77.01 bill for a revised monthly bill of $81.08 effective Jan. 1, 2024.

2024 Natural Gas Revenue Impact by Rate Schedule
Rate Schedule Description 2024 Billing Change
Residential Schedule 410 5.1%
General Service Schedule 420 5.8%
Large General Service Schedules 424 & 425 0.1%
Interruptible Service Schedule 439 & 440 0.1%
Seasonal Service Schedule 444 0.2%
Transportation Service Schedule 456 0.8%
Total   4.7
%

The actual percentage rate change will vary by customer rate schedule and will depend on how much energy a customer uses.

Avista serves approximately 106,000 customers in Oregon.


Customer Resources

To assist customers in managing their energy bills, Avista offers services for customers such as comfort level billing, payment arrangements and Customer Assistance Referral and Evaluation Services (CARES), which provide assistance to special-needs customers through referrals to area agencies and churches for help with housing, utilities, medical assistance and other needs. Avista also provides funding for energy assistance programs Project Share and the company’s LIRAP, which are administered through community action agencies.

Avista provides energy efficiency and outreach programs that include rebates and incentives as well as tips and resources to help customers manage their energy use and energy bills. Customers can learn more at www.myavista.com.

About Avista Corp.

Avista Corp. is an energy company involved in the production, transmission, and distribution of energy as well as other energy-related businesses. Avista Utilities is the operating division that provides electric service to 403,000 customers and natural gas to 369,000 customers. Its service territory covers 30,000 square miles in eastern Washington, northern Idaho, and parts of southern and eastern Oregon, with a population of 1.6 million. Alaska Energy and Resources Company is an Avista subsidiary that provides retail electric service in the city and borough of Juneau, Alaska, through its subsidiary Alaska Electric Light and Power Company. Avista stock is traded under the ticker symbol “AVA.” For more information about Avista, please visit www.avistacorp.com.

This news release contains forward-looking statements regarding the company’s current expectations. Forward-looking statements are all statements other than historical facts. Such statements speak only as of the date of the news release and are subject to a variety of risks and uncertainties, many of which are beyond the company’s control, which could cause actual results to differ materially from the expectations. These risks and uncertainties include, in addition to those discussed herein, all of the factors discussed in the company’s Annual Report on Form 10-K for the year ended Dec. 31, 2022 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

SOURCE: Avista Corporation

Contact:

Media: Lena Funston (509) 495-8090, [email protected]
Investors: Stacey Wenz (509) 495-2046, [email protected]
Avista 24/7 Media Access (509) 495-4174



UPDATE — Clearfield Reports Fiscal Third Quarter 2023 Results

MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) — In the release issued earlier today by Clearfield, Inc. (NASDAQ: CLFD) under the same headline, please note that the updated press release below now includes the Consolidated Balance Sheets and omits a duplicate Cashflows table.

  • Record international revenues driven by the performance of Nestor Cables.

  • Reiterates revenue guidance and increases net income per share guidance to $2.05 to $2.15 for fiscal year 2023.


Clearfield, Inc.

(NASDAQ: CLFD), a leader in fiber connectivity, reported results for the third quarter of fiscal 2023.  

Fiscal Q3 2023 Financial Summary  
(in millions except per share data and percentages) Q3 2023 vs. Q3 2022 Change Change (%)
Net Sales $ 61.3   $ 71.3   $ (10.0 ) -14 %
         
Gross Profit ($) $ 19.1   $ 29.3   $ (10.2 ) -35 %
Gross Profit (%)   31.1 %   41.1 %   -10.0 % -24 %
         
Income from Operations $ 5.6   $ 16.6   $ (11.0 ) -66 %
Income Tax Expense $ 1.8   $ 3.9   $ (2.0 ) -53 %
         
Net Income $ 5.2   $ 12.7   $ (7.5 ) -59 %
Net Income per Diluted Share $ 0.33   $ 0.92   $ (0.59 ) -64 %
         

Fiscal Q3 YTD 2023 Financial Summary  
(in millions except per share data and percentages) 2023 YTD vs. 2022 YTD Change Change (%)
Net Sales $ 219.0   $ 175.9   $ 43.2   25 %
         
Gross Profit ($) $ 73.3   $ 75.4   $ (2.2 ) -3 %
Gross Profit (%)   33.5 %   42.9 %   -9.4 % -22 %
         
Income from Operations $ 35.6   $ 41.6   $ (6.0 ) -14 %
Income Tax Expense $ 8.5   $ 9.5   $ (1.0 ) -10 %
         
Net Income $ 29.8   $ 32.4   $ (2.5 ) -8 %
Net Income per Diluted Share $ 2.00   $ 2.33   $ (0.33 ) -14 %
         

Management Commentary

“Our third quarter fiscal 2023 results came in relatively in-line with our expectations,” said Company President and CEO Cheri Beranek. “Based on conversations with our customers, we expect service providers to continue working through inventory for the next several quarters. Additionally, our community broadband customers are adopting a cautious approach with respect to deploying capital until they have better visibility into the timing of government funded deployments. While we expect these dynamics will impact our near-term performance, likely into fiscal 2024, we continue to focus on positioning the company for long-term growth, right-sizing capacity levels, and designing products that address our customers’ biggest pain points. With government funding initiatives underway and significant rural broadband builds expected in the coming years, we anticipate strong demand for our core products once order patterns return to normalized levels. By investing in our people, modernizing our systems, and targeting expansion into new markets like Europe, we are positioning Clearfield for continued success which we believe will drive significant shareholder value over the long term.”

“Clearfield’s strong balance sheet and strategic approach with service providers enable us to pursue growth opportunities and enhance our product portfolio,” said CFO Dan Herzog. “We continue to invest in capital equipment with faster processing capability to reduce costs and improve margins. Finally, we are reiterating our full-year fiscal 2023 revenue guidance and increasing our full year net income per share guidance.”


Financial Results for the Three Months Ended June 30, 2023


Net sales for the third quarter of fiscal 2023 decreased 14% to $61.3 million from $71.3 million in the same year-ago quarter. Organic revenue decreased 33% year over year to $47.9 million, while Nestor Cables generated revenue of $13.4 million.

As of June 30, 2023, order backlog (defined as purchase orders received but not yet fulfilled) was $74.7 million, a decrease of $32.9 million, or 31% compared to $107.6 million as of March 31, 2023, and a decrease of $82.0 million, or 52%, from June 30, 2022. The sequential decrease was due to a lull in demand as customers digest previously purchased products.

Gross margin for the quarter was 31.1%, compared to 41.1% in the third quarter of fiscal 2022. Gross margin was negatively affected by excess production capacity as well as Nestor’s inclusion in the quarter. The Company continues to realign capacity to current market conditions.

Operating expenses for the quarter increased 6% to $13.4 million, or 22% of net sales, from $12.7 million, or 18% of net sales in the same year-ago quarter.

Net income for the quarter totaled $5.2 million, or $0.33 per diluted share, compared to $12.7 million, or $0.92 per diluted share, in the same year-ago quarter.

Outlook

The Company is reiterating its fiscal 2023 revenue guidance and is raising its net income per share guidance due to better-than-expected product margin as well as cost saving initiatives. Clearfield continues to expect its full year fiscal 2023 net sales to be within a range of $260 to $275 million, and now expects net income per share to be in the range of $2.05 to $2.15, up from $1.80 to $2.10 previously.

Conference Call

Management will hold a conference call today, August 3, 2023, at 5:00 p.m. Eastern Time (4:00 p.m. Central Time) to discuss these results and provide an update on business conditions.

Clearfield’s President and CEO Cheri Beranek and CFO Dan Herzog will host the presentation, followed by a question-and-answer period.

U.S. dial-in: 1-844-826-3033
International dial-in: 1-412-317-5185
Conference ID: 8040539

The live webcast of the call can be accessed at the Clearfield Investor Relations website along with the company’s earnings press release and presentation.

Please see the Earnings Presentation for recharacterized customer segment revenue.

A replay of the call will be available after 8:00 p.m. Eastern Time on the same day through August 17, 2023, while an archived version of the webcast will be available on the Investor Relations website for 90 days.

U.S. replay dial-in: 1-844-512-2921
International replay dial-in: 1-412-317-6671
Replay ID: 10177264

About Clearfield, Inc.

Clearfield, Inc. (NASDAQ: CLFD) designs, manufactures, and distributes fiber optic management, protection, and delivery products for communications networks. Our “fiber to anywhere” platform serves the unique requirements of leading incumbent local exchange carriers (traditional carriers), competitive local exchange carriers (alternative carriers), and MSO/cable TV companies, while also catering to the broadband needs of the utility/municipality, enterprise, data center, and military markets. Headquartered in Minneapolis, MN, Clearfield deploys more than a million fiber ports each year. For more information, visit www.SeeClearfield.com.

Cautionary Statement Regarding Forward-Looking Information

Forward-looking statements contained herein and in any related presentation or in the related Earnings Presentation are made pursuant to the safe harbor provisions of the Private Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “outlook,” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, statements about the Company’s future revenue and operating performance, expected customer ordering patterns, anticipated shipping on backlog and future lead times, future availability of components and materials from the Company’s supply chain, future availability of labor impacting our customers’ network builds, the impact of the Rural Digital Opportunity Fund (RDOF) or other government programs on the demand for the Company’s products or timing of customer orders, the Company’s ability to match capacity to meet demand, expansion into new markets and trends in and growth of the FTTx markets, market segments or customer purchases and other statements that are not historical facts. These statements are based upon the Company’s current expectations and judgments about future developments in the Company’s business. Certain important factors could have a material impact on the Company’s performance, including, without limitation: the COVID-19 pandemic has significantly impacted worldwide economic conditions and could have a material adverse effect on our business, financial condition and operating results;
inflationary price pressures and uncertain availability of components, raw materials, labor and logistics used by us and our suppliers could negatively impact our profitability; we rely on single-source suppliers, which could cause delays, increase costs or prevent us from completing customer orders; we depend on the availability of sufficient supply of certain materials and global disruptions in the supply chain for these materials could prevent us from meeting customer demand for our products; we rely on our manufacturing operations to produce product to ship to customers and manufacturing constraints and disruptions could result in decreased future revenue; a significant percentage of our sales in the last three fiscal years have been made to a small number of customers, and the loss of these major customers could adversely affect us; further consolidation among our customers may result in the loss of some customers and may reduce sales during the pendency of business combinations and related integration activities; we may be subject to risks associated with acquisitions, and the risks could adversely affect future operating results; we have exposure to movements in foreign currency exchange rates; if we are unable to integrate acquired businesses, our financial results could be materially and adversely affected; adverse global economic conditions and geopolitical issues could have a negative effect on our business, and results of operations and financial condition; our planned growth may strain our business infrastructure, which could adversely affect our operations and financial condition; product defects or the failure of our products to meet specifications could cause us to lose customers and sales or to incur unexpected expenses; we are dependent on key personnel; cyber-security incidents on our information technology systems, including ransomware, data breaches or computer viruses, could disrupt our business operations, damage our reputation, and potentially lead to litigation; our business is dependent on interdependent management information systems;
to compete effectively, we must continually improve existing products and introduce new products that achieve market acceptance; if the telecommunications market does not continue to expand, our business may not grow as fast as we expect, which could adversely impact our business, financial condition and operating results; changes in U.S. government funding programs may cause our customers and prospective customers to delay, reduce, or accelerate purchases, leading to unpredictable and irregular purchase cycles; intense competition in our industry may result in price reductions, lower gross profits and loss of market share;
our success depends upon adequate protection of our patent and intellectual property rights; we face risks associated with expanding our sales outside of the United States; and other factors set forth in Part I, Item IA. Risk Factors of Clearfield’s Annual Report on Form 10-K for the year ended September 30, 2022 as well as other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements to reflect actual events unless required by law.

Investor Relations Contact:

Greg McNiff
The Blueshirt Group
773-485-7191
[email protected]

                       
CLEARFIELD, INC.                      
CONSOLIDATED STATEMENTS OF OPERATIONS                  
(UNAUDITED)                      
(IN THOUSANDS, EXCEPT SHARE DATA)                      
  (Unaudited)   (Unaudited)
  Three Months Ended   Nine Months Ended
  June 30,   June 30,
    2023       2022     2023       2022
                       
Net sales $ 61,284     $ 71,250   $ 219,035     $ 175,854
                       
Cost of sales   42,210       41,943     145,750       100,411
                       
Gross profit   19,074       29,307     73,285       75,443
                       
Operating expenses                      
Selling, general and                      
administrative   13,449       12,721     37,714       33,877
Income from operations   5,625       16,586     35,571       41,566
                       
Net investment income   1,630       43     3,328       284
Interest expense   (195 )         (551 )    
Income before income taxes   7,060       16,629     38,348       41,850
                       
Income tax expense   1,842       3,884     8,511       9,480
                       
Net income $ 5,218     $ 12,745   $ 29,837     $ 32,370
                       
Net income per share:                      
Basic $ 0.33     $ 0.93   $ 2.01     $ 2.35
Diluted $ 0.33     $ 0.92   $ 2.00     $ 2.33
                       
Weighted average shares outstanding:                      
Basic   15,254,341       13,772,269     14,880,666       13,760,950
Diluted   15,254,341       13,899,698     14,929,405       13,900,019
                       

CLEARFIELD, INC.          
CONSOLIDATED BALANCE SHEETS          
(IN THOUSANDS, EXCEPT SHARE DATA)          
    (Unaudited)      
    June 30,     September 30,
    2023       2022  
Assets          
Current Assets          
Cash and cash equivalents $ 31,385     $ 16,650  
Short-term investments   130,726       5,802  
Accounts receivable, net   31,944       53,704  
Inventories, net   105,003       82,208  
Other current assets   4,084       1,758  
Total current assets   303,142       160,122  
           
Property, plant and equipment, net   21,318       18,229  
           
Other Assets          
Long-term investments   6,556       22,747  
Goodwill   6,581       6,402  
Intangible assets, net   6,344       6,376  
Right-of-use lease assets   14,773       13,256  
Deferred tax asset   998       1,414  
Other   1,489       582  
Total other assets   36,741       50,777  
Total Assets $ 361,201     $ 229,128  
           
Liabilities and Shareholders’ Equity          
Current Liabilities          
Current portion of lease liability $ 3,722     $ 3,385  
Debt   2,174        
Accounts payable   11,641       24,118  
Accrued compensation   7,319       13,619  
Accrued expenses   3,335       6,181  
Factoring liability   8,722       4,391  
Total current liabilities   36,913       51,694  
           
Other Liabilities          
Long-term debt         18,666  
Long-term portion of lease liability   11,572       10,412  
Deferred tax liability   782       774  
Total Liabilities   49,267       81,546  
           
Shareholders’ Equity          
Common stock   153       138  
Additional paid-in capital   187,409       54,539  
Accumulated other comprehensive loss   (268 )     (1,898 )
Retained earnings   124,640       94,803  
Total Shareholders’ Equity   311,934       147,582  
Total Liabilities and Shareholders’ Equity $ 361,201     $ 229,128  
           

Clearfield, Inc.            
Consolidated Statement of Cashflows            
(Unaudited)            
      Nine Months Ended   Nine Months Ended
      June 30,   June 30,
      2023   2022
  Cash flows from operating activities            
  Net income   $ 29,837     $ 32,370  
  Adjustments to reconcile net income to cash provided            
  by (used in) operating activities:            
  Depreciation and amortization     4,411       2,205  
  Amortization of discount on investments     (2,429 )     (31 )
  Stock-based compensation     2,504       1,647  
  Changes in operating assets and liabilities            
  Accounts receivable     24,519       (12,156 )
  Inventories, net     (21,510 )     (41,816 )
  Other assets     (3,525 )     (185 )
  Accounts payable and accrued expenses     (20,326 )     8,677  
  Net cash provided by (used in) operating activities     13,481       (9,289 )
               
  Cash flows from investing activities:            
  Purchases of property, plant and equipment and            
  intangible assets     (6,529 )     (6,764 )
  Purchase of investments     (210,923 )     (248 )
  Proceeds from sales and maturities of investments     105,077       17,386  
  Net cash (used in) provided by investing activities     (112,375 )     10,374  
               
  Cash flows from financing activities:            
  Repayment of long-term debt     (16,700 )      
  Proceeds from issuance of common stock under     612       544  
  employee stock purchase plan            
  Repurchase of shares for payment of withholding taxes     (954 )     (274 )
  for vested restricted stock grants            
  Tax withholding and proceeds related to exercise of stock options   (493 )     (379 )
  Issuance of stock under equity compensation plans     954        
  Net proceeds from issuance of common stock     130,262        
  Net cash provided by (used in) financing activities     113,681       (109 )
               
  Effect of exchange rates on cash     (52 )      
  Increase in cash and cash equivalents     14,735       976  
  Cash and cash equivalents, beginning of period     16,650       13,216  
  Cash and cash equivalents, end of period   $ 31,385     $ 14,192  
               
  Supplemental disclosures for cash flow information            
  Cash paid for income taxes   $ 12,589     $ 9,913  
  Cash paid for interest   $ 360     $  
               
  Non-cash financing activities            
  Cashless exercise of stock options   $ 566     $ 276  
               



NHC Announces Common Dividend

NHC Announces Common Dividend

MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 59 cents per common share to shareholders of record on September 29, 2023 and payable on November 1, 2023.

Forward-Looking Statements

Statements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q and 10-K, and include, among others, the following: liabilities and other claims asserted against us and patient care liabilities, as well as the resolution of current litigation; availability of insurance and assets for indemnification; national and local economic conditions; including their effect on the availability and cost of labor, utilities and materials; the effect of government regulations and changes in regulations governing the healthcare industry, including our compliance with such regulations; changes in Medicare and Medicaid payment levels and methodologies and the application of such methodologies by the government and its fiscal intermediaries, the ability of third parties for whom we have guaranteed debt to refinance certain short term debt obligations; and other factors referenced or incorporated by reference in the S.E.C. filings. The risks included here are not exhaustive. All forward-looking statements represent NHC’s best judgment as of the date of this release.

About NHC

NHC affiliates operate for themselves and third parties 68 skilled nursing facilities with 8,732 beds. NHC affiliates also operate 23 assisted living communities with 1,181 units, five independent living communities with 475 units, three behavioral health hospitals, 35 homecare agencies, and 30 hospice agencies. NHC’s other services include Alzheimer’s and memory care units, pharmacy services, a rehabilitation services company, and providing management and accounting services to third party post-acute operators. Other information about the company can be found on our web site at www.nhccare.com.

Brian F. Kidd, SVP/Chief Financial Officer

Phone: (615) 890-2020

KEYWORDS: United States North America Tennessee

INDUSTRY KEYWORDS: Nursing Physical Therapy Managed Care Health General Health Seniors Pharmaceutical Mental Health Family Hospitals Consumer

MEDIA:

Logo
Logo

Arrow Electronics to Participate in Upcoming Investor Events

Arrow Electronics to Participate in Upcoming Investor Events

CENTENNIAL, Colo.–(BUSINESS WIRE)–
Arrow Electronics, Inc. (NYSE:ARW) today announced its management is scheduled to participate in the following investor events:

  • KeyBanc Capital Markets, 24th Annual Technology Leadership Forum on Tuesday, Aug. 8, 2023, at the Grand Hyatt in Vail, Colo.

  • Jefferies Semiconductor, IT Hardware & Communications Technology Summit on Wednesday, Aug. 30, 2023, at the Four Seasons Hotel in Chicago, Ill.

  • Deutsche Bank, 2023 Technology Conference on Thursday, Aug. 31, 2023, at the Waldorf Astoria Monarch Beach – Dana Point, Calif.

  • Citi’s 2023 Global Technology Conference on Wednesday, Sept. 6, 2023, at the New York Hilton Midtown, in New York, N.Y.

  • Jefferies Industrials Conference on Thursday, Sept. 7, 2023, at the New York Marriott Marquis.

Management will be available to meet one-on-one with investors during the conferences. Interested investors should contact their respective representatives to secure a meeting time.

About Arrow Electronics

Arrow Electronics guides innovation forward for over 210,000 leading technology manufacturers and service providers. With 2022 sales of $37 billion, Arrow develops technology solutions that help improve business and daily life. Learn more at fiveyearsout.com.

Investors:

Anthony Bencivenga | Vice President, Investor Relations | 303-566-7456 | [email protected]

Media:

John Hourigan | Vice President, Public Affairs and Corporate Marketing | 303-824-4586 | [email protected]

KEYWORDS: Illinois Colorado California New York United States North America

INDUSTRY KEYWORDS: Software Internet Other Manufacturing Hardware Data Management Technology Manufacturing Other Technology

MEDIA:

Logo
Logo